Im vergangenen Jahr erzielte OraSure Technologies Inc für sein leistungsstärkstes Segment, Net product and services revenues - HIV, Einnahmen von 49.80M USD. Die Region United States leistete den größten Beitrag mit 78.25M USD im letzten Jahr. Im letzten Quartal berichtete OraSure Technologies Inc über Einnahmen in Höhe von 14.17M USD für den Zeitraum bis zum 2026-06-30, die aus dem leistungsstärksten Segment, Net product and services revenues - COVID-19, stammten. United States trug mit 20.23M USD den höchsten Umsatz bei.

Nach Geschäftsbereich

Umsatz

Anteil

Jährlich

Jährlich

Vierteljährlich

Net product and services revenues - HIV

Net product and services revenues - Microbiome

Net product and services revenues - HCV

Other revenues - Other non Product revenues

Net product and services revenues - Other Products revenue

Other revenues

Net product and services revenues - Risk assessment testing

Net product and services revenues - COVID-19

Net product and service revenues -Molecular Services

Net product and service revenues -Molecular Products

Net product and services revenues - Genomics

Net product and services revenues - Laboratory services

Other revenues - Royalty Income

Net product and services revenues - Infectious disease testing

Net product and services revenues - OraQuick

Net product and services revenues - Oragene

Net product and services revenues - ORAcollect

Net product and services revenues - Intercept

Net product and services revenues - Microbiome laboratory services

Net product and services revenues - Histofreezer

Net product and services revenues - OMNIgene® • GUT

Research and development funding

Grant funding

Charitable Support reimbursement

BARDA Funding

AbbVie Exclusivity

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

Net product and services revenues - HIV

49.80M(41.62%)

60.80M(32.11%)

60.82M(14.92%)

38.81M(9.94%)

--(--)

Net product and services revenues - Microbiome

38.36M(32.05%)

--(--)

7.50M(1.92%)

7.94M(3.36%)

6.16M(3.58%)

--(--)

Net product and services revenues - HCV

13.76M(11.50%)

14.02M(7.41%)

12.87M(3.16%)

13.37M(3.42%)

--(--)

Other revenues - Other non Product revenues

5.97M(4.99%)

1.22M(0.64%)

3.25M(0.80%)

6.75M(1.73%)

2.36M(1.00%)

1.91M(1.11%)

--(--)

Net product and services revenues - Other Products revenue

4.65M(3.88%)

3.51M(1.85%)

2.27M(0.56%)

3.14M(0.80%)

2.57M(1.09%)

117.00K(0.07%)

9.52M(5.80%)

19.04M(9.48%)

Other revenues

4.65M(3.88%)

3.51M(1.85%)

2.27M(0.56%)

3.14M(0.80%)

2.57M(1.09%)

117.00K(0.07%)

9.52M(5.80%)

19.04M(9.48%)

Net product and services revenues - Risk assessment testing

1.87M(1.56%)

8.35M(4.41%)

9.74M(2.39%)

10.27M(2.63%)

9.68M(4.10%)

9.37M(5.46%)

--(--)

Net product and services revenues - COVID-19

624.00K(0.52%)

45.17M(23.86%)

257.78M(63.22%)

243.32M(62.29%)

76.87M(32.54%)

49.80M(28.98%)

--(--)

Net product and service revenues -Molecular Services

--(--)

1.71M(0.90%)

4.47M(1.10%)

--(--)

Net product and service revenues -Molecular Products

--(--)

51.05M(26.96%)

54.27M(13.31%)

--(--)

Net product and services revenues - Genomics

--(--)

54.34M(13.91%)

63.35M(26.82%)

37.14M(21.61%)

--(--)

Net product and services revenues - Laboratory services

--(--)

7.30M(1.87%)

11.84M(5.01%)

9.56M(5.57%)

--(--)

Other revenues - Royalty Income

--(--)

2.68M(0.69%)

4.42M(1.87%)

3.43M(2.00%)

5.12M(3.12%)

9.65M(4.81%)

Net product and services revenues - Infectious disease testing

--(--)

54.65M(23.13%)

54.23M(31.56%)

--(--)

Net product and services revenues - OraQuick

--(--)

56.06M(34.16%)

53.85M(26.82%)

Net product and services revenues - Oragene

--(--)

46.70M(28.45%)

75.85M(37.78%)

Net product and services revenues - ORAcollect

--(--)

10.65M(6.49%)

--(--)

Net product and services revenues - Intercept

--(--)

8.11M(4.94%)

7.71M(3.84%)

Net product and services revenues - Microbiome laboratory services

--(--)

6.10M(3.72%)

--(--)

Net product and services revenues - Histofreezer

--(--)

5.70M(3.47%)

8.98M(4.47%)

Net product and services revenues - OMNIgene® • GUT

--(--)

5.23M(3.18%)

--(--)

Research and development funding

--(--)

851.00K(0.52%)

--(--)

Grant funding

--(--)

304.00K(0.19%)

--(--)

Charitable Support reimbursement

--(--)

261.00K(0.16%)

1.71M(0.85%)

BARDA Funding

--(--)

4.95M(2.47%)

AbbVie Exclusivity

--(--)

Nach Region

Umsatz

Anteil

Jährlich

Jährlich

Vierteljährlich

United States

Africa (Region)

Europe

Other Regions

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

FY2014

FY2013

FY2012

FY2011

United States

78.25M(68.03%)

139.16M(74.89%)

361.66M(89.19%)

350.21M(90.38%)

188.38M(80.62%)

130.84M(76.19%)

107.28M(69.39%)

136.85M(75.30%)

121.46M(72.70%)

99.76M(77.82%)

96.52M(80.62%)

82.26M(77.26%)

77.19M(78.02%)

67.46M(76.82%)

67.64M(82.61%)

Africa (Region)

23.99M(20.86%)

32.74M(17.62%)

--(--)

Europe

7.39M(6.43%)

8.42M(4.53%)

8.11M(2.00%)

11.54M(2.98%)

13.80M(5.91%)

12.07M(7.03%)

11.75M(7.60%)

11.06M(6.09%)

11.83M(7.08%)

11.65M(9.08%)

13.54M(11.31%)

13.91M(13.07%)

11.08M(11.20%)

10.13M(11.54%)

7.51M(9.17%)

Other Regions

5.38M(4.68%)

5.50M(2.96%)

35.70M(8.80%)

25.74M(6.64%)

31.49M(13.48%)

28.82M(16.78%)

35.57M(23.01%)

33.83M(18.62%)

33.78M(20.22%)

16.79M(13.10%)

9.66M(8.07%)

10.29M(9.67%)

10.66M(10.78%)

10.23M(11.65%)

6.73M(8.22%)